FDA Proposes Streamlining Intercenter Agreements On Combo Products
This article was originally published in The Pink Sheet Daily
Agreement signed in 1991 between drug and biologics centers should be rescinded.
You may also be interested in...
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.